Nine therapies have outgrown the IPM growth
The Indian Pharmaceutical Market clocked Rs 8328 crores in July 2015. It has grown at 12.9 per cent in the same month. Amongst the top 10, Lupin grew by 25.1 per cent followed by Sun at 21.8 per cent and Pfizer at 17.2 per cent. 19 corporates have crossed the growth of IPM for July 2015 amongst top 50.
Amongst the top 50 corporates, AstraZeneca has the highest growth of 36.1 per cent followed by Bharat Serums at 34.6 per cent and Intas at 32.6 per cent. 25 corporates have shown growths more than 10 per cent amongst the top 50. Amongst the 11-20 ranked corporate Intas has the highest growth of 32.6 per cent followed by Glenmark at 30.9 per cent and USV at 21.7 per cent.
Amongst the 21-30 ranked corporates, MSD has the highest growth at 30.6 per cent followed by Wockhardt 30.2 per cent and Novartis at 14.1 per cent. Amongst the 31-40 ranked corporates, AstraZeneca has the highest growth at 36.1 per cent followed by Bharat Serums at 34.6 per cent and JBCPL at 22.8 per cent. Amongst the 41-50 ranked corporates, Wallace has the highest growth at 17.8 per cent followed by Win-Medicare at 9.8 per cent and Fourrts at 9.3 per cent.
Amongst the 51-60 ranked corporates, Boehringer grew at 84 per cent followed by Troikaa at 35.4 per cent and Eli Lilly at 32.3 per cent. Amongst the 61-70 ranked corporates, Fresenius Kabi grew at 60.6 per cent followed by RPG at by 34.3 per cent followed by TTK at 21.6 per cent. Intas moves to number 11 and Novartis to number 21, Eris to 29th , Hetero to 40th rank in the IPM as on MAT July 2015. DRL has crossed the Rs 2000-crore mark with the addition of UCB portfolio that had been acquired. Wallace has entered the Rs 400-crore club on MAT basis.
For the month of July 2015, amongst the top 10, Lupin grew by 25.1 per cent followed by Sun Pharma at 22.7 per cent and Ranbaxy at 20.4 per cent. 22 companies have crossed the growth of IPM for the month of July 2015 amongst top 50. Amongst the 21-30 ranked companies, Wockhardt has the highest growth at 30.2 per cent followed by Novo Nordisk 25.5 per cent and Zuventus at 16 per cent.
Indian companies have grown at 12.6 per cent versus 13.8 per cent for MNCs in July 2015. Amongst the top 50 in MNCs, AstraZeneca grew at 36.1 per cent, MSD grew by 30.6 per cent followed by Pfizer at 17.2 per cent. Under the non-NLEM category, Indian companies grew at four per cent whereas MNCs grew at 8.4 per cent.
The DPCO containing molecules market grew at 5.1 per cent whereas the non-DPCO market grew by 14.2 per cent and Non -Sch Para 19 Market at 11.8 per cent resulting in an overall growth of 12.9 per cent for July 2015. NLEM & Non – NLEM category showed unit growth at -0.6 per cent and 4.1 per cent respectively. The non-Sch Para 19 Market grew at 9.9 per cent from units perspective The DPCO 2013 portfolio for Pfizer grew at 13 per cent, Ranbaxy 20.5 per cent, GSK at -2.1 per cent and Abbott Healthcare 7.2 per cent.
From therapy perspective, nine therapies have outgrown the IPM growth. The respiratory market grew at 9.6 per cent, gastrointestinal market grew at 16.2 per cent , pain and analgesics market grew at 9.6 per cent whereas anti-infectives grew at 1.6 per cent.
The anti-diabetic market grows at 25.4 per cent and cardiac at 17.1 per cent in chronic business. The derma market grew by 19.4 per cent and urology market at 18.6 per cent.
From regional perspective, 15 regions have outgrown the IPM growth. The North AP market grew the highest at 21.6 per cent followed by Punjab market at 20.9 per cent and Mumbai City market at 19.6 per cent. No region had negative growth in July 2015. Amoxycillin + Clavulanic acid market grew at -3.4 per cent whereas glimepiride+metformin grows at 15.5 per cent at number two.
The markets of paracetamol grew at 2.2 per cent, atorvastatin 12 per cent, probiotic microbes at 36.7 per cent, cefixime -1.4 per cent, pantoprazole 16.8 per cent, montelukast + levocetrizine at 10.8 per cent, glimepiride + metformin + pioglitazone at 16.4 per cent, vitamin-D at 27.1 per cent, hydroquinone + mometasone + tretinoin at 18.3 per cent, voglibose + metformin + glimepiride at 56.8 per cent, rosuvastatin at 28.2 per cent, protein supplements at 13.9 per cent, azithromycin at -5.3 per cent, calcium Carbonate + Vit D3 market at 41.4 per cent.
Mixtard leads the pack with Rs 42 crores followed by spasmoproxyvon plus at Rs 30 crores and glycomet-GP at Rs 28 crores for July 15. phensedyl cough grew by 133.1 per cent followed by corex at 103.1, janumet at 93.4 per cent, spasmoproxyvon plus 70.4 per cent, mixtard at 37.4 per cent and glycomet-GP at 18.4 per cent amongst the top 10 brands.
Few brands who have gained ranks include betnesol (+108), Pantocid D SR (+77), Eltroxin (+57), Phensedyl cough (+55), Chymoral Forte (+48), Istamet (+45), Janumet (+42), Jalra M (+41), Budecort & Huminsulin (+36), Pantocid & Omez (+33), Rosuvas (+28), Vertin (+26), Corex & Shelcal (+24), Magnex & Rantac (+22), Jalra (+20), Susten & Betnovate N (+19), Galvus (+17), Ascoril Plus (+16), Betnovate C & Aztor (+15), Levipil (+14), Telma (+12) amongst top 100 brands over July -14. Few brands that have moved up ranks fastest into top 300 brands for the month of July – 15 are Biovac V, Brilinta, Oframax, Enteroquinol, Monocef SB, Bevon, Glycomet Trio, Primolut N Uprise D3 amongst others. 300th biggest brand is Livogen from Merck. A total of 291 brands and 545 SKUs were launched in July 2015. Top new brands for July -15 were Cerebrolysin, Caripill & Kofarest PD. Biggest new launch by an MNC are Anzavir R, Sequadra & Daracept in July 2015.
About PharmaTrac
PharmaTrac is a the secondary sales data audit conducted by AIOCD Pharmasofttech AWACS, a pharmaceutical market research company formed by All Indian Origin Chemists & Distributors (AIOCD ) in a joint venture with Trikaal Mediinfotech. AWACS (Advanced Working, Action & Correction System) reflects the underlying philosophy behind AIOCD AWACS’ research tools to reduce time to information by 50 per cent or more and to significantly improve on accuracy of information.
Terminologies used
MAT – Moving Annual Total
MTH – Month
Val (Cr) – Value in Crores
MS per cent – Market Share in Percentage
GR per cent – Growth in percentage.
For more information, visit http://www.aiocd.net